Soon after Murray Kessler joined Perrigo Company PLC as president and CEO in 2018, Ireland hit the firm “out of nowhere” with a €1.6bn ($1.9bn) tax assessment.
Kessler Exits Perrigo With Doors Open On Turnaround, Closed On Ireland, US Tax Disputes
At helm nearly five years with Perrigo continuing to navigate comprehensive turnaround with a target of returning to its historical profile of driving volume sales while keeping costs lower than is brand-name OTC drug competitors, he’s leaving at end of July.
More from Leadership
• By
A round-up of the latest industry moves in Europe: Pharma Deutschland elects board of new Brussels operation; MHRA's new CEO gets to work; Futura names non-executive director.
• By
The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.
• By
Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
More from HBW Insight
• By
Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. “If we reauthorize it, will it continue?” Texas representative Lizzie Fletcher asks of OMUFA.
• By
Single-use packaging producers subject to Oregon state’s Extended Producer Responsibility law that didn’t meet the 31 March deadline to report their packaging materials are given a grace period to report until 30 April, says Circular Action Alliance, the organization carrying out the EPR program.
• By
Reclassifying ethanol as a carcinogenic, mutagenic, or reprotoxic substance - something the European Chemicals Agency seems likely to do in the near future - would be “tantamount to a de facto ban” with “fatal consequences” for medical care in Germany, says Pharma Deutschland in a joint paper with 13 other German healthcare industry associations.